MedTrace Logo

Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

NCT01463683 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 722

Last updated 2018-07-18

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.

Conditions

Interventions

BIOLOGICAL

2XP HEPTAVAX™-II SC

BIOLOGICAL

1XP HEPTAVAX™-II SC

BIOLOGICAL

2XP HEPTAVAX™-II IM

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-29
Primary Completion
2012-11-06
Completion
2012-11-06

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01463683 on ClinicalTrials.gov